Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Hwang, Deok Won | - |
dc.contributor.author | Ko, Young Hyeh | - |
dc.contributor.author | Tang, Tiffany | - |
dc.contributor.author | Lim, Soon Thye | - |
dc.contributor.author | Kim, Won Seog | - |
dc.date.available | 2020-02-29T00:41:57Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-04 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14644 | - |
dc.description.abstract | Extranodal natural killer/T-cell lymphoma (ENKL) has a dismal prognosis. Although L-asparaginase has shown promising efficacy as a frontline therapy, currently there are no treatment options after progression to an L-asparaginase-containing regimen. We report the results of gemcitabine-containing therapy in patients with relapsed or refractory ENKL. We retrospectively reviewed 20 patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen between 2005 and 2011. The overall response rate was 40 % (8 of 20 patients) with a complete response (CR) rate of 20 % (n = 4) and a partial response (PR) rate of 20 % (n = 4). Four complete responders had a disease-free status for more than 7 months including two patients received autologous stem cell transplantation consolidation and L-aspraginase maintenance, respectively. The median progression-free survival of the 20 patients was 2.3 months; however, it was 7.3 months for eight responders (CR and PR). The median overall survival of the eight responders had not been reached at the time of analysis. Gemcitabine was effective in a subset of pretreated ENKL patients and can be considered as a salvage option. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | INVESTIGATIONAL NEW DRUGS | - |
dc.subject | T-CELL | - |
dc.subject | NASAL-TYPE | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | CHOP | - |
dc.subject | MULTICENTER | - |
dc.subject | RESISTANCE | - |
dc.title | Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000316081900025 | - |
dc.identifier.doi | 10.1007/s10637-012-9889-4 | - |
dc.identifier.bibliographicCitation | INVESTIGATIONAL NEW DRUGS, v.31, no.2, pp.469 - 472 | - |
dc.identifier.scopusid | 2-s2.0-84879549921 | - |
dc.citation.endPage | 472 | - |
dc.citation.startPage | 469 | - |
dc.citation.title | INVESTIGATIONAL NEW DRUGS | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Extranodal NK/Tcell lymphoma | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Salvage | - |
dc.subject.keywordPlus | T-CELL | - |
dc.subject.keywordPlus | NASAL-TYPE | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | CHOP | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.